MTOR and cancer: Various reports have identified cancer relevant pathways, including the vascular endothelial growth factor (VEGF) receptor [44, 45], the cyclooxygenase-2 (COX-2) [46, 47], epidermal growth factor receptor (EGFR) [48], and mammalian target of rapamycin (mTOR) [49], as EC treatment targets.